How Much Bacteriostatic Water for PT-141? (Chart)

Reconstitution Volume Overview for PT-141 Vials

Reconstituting PT-141 typically requires adding 1.0 mL to 2.0 mL of bacteriostatic water per 10 mg lyophilized vial, depending on the target concentration required for specific in vitro assay protocols or micro-dispensing equipment. Because lyophilized peptides are stable dry powders, adding a sterile diluent containing 0.9% benzyl alcohol—such as bacteriostatic water—allows researchers to solubilize the peptide while inhibiting microbial growth during multi-use laboratory testing.

Choosing an appropriate volume of bacteriostatic water depends primarily on the required target concentration and the volumetric precision of your lab's pipetting instruments. High-density stock concentrations (e.g., 10 mg/mL) minimize total volumetric addition to assay media, while lower concentrations (e.g., 2 mg/mL or 5 mg/mL) allow finer volumetric control when aliquoting smaller mass increments. To explore additional research-grade compounds, review our comprehensive catalog of all peptides available for laboratory purchase.

PT-141 Reconstitution Dilution Chart

The following reference chart details the resulting stock concentration when diluting a standard PT-141 10mg lyophilized vial across common diluent volumes (1.0 mL, 2.0 mL, 3.0 mL, and 5.0 mL of bacteriostatic water).

• 1.0 mL Diluent Volume: Reconstituting a 10 mg vial with 1.0 mL of bacteriostatic water yields a stock concentration of 10.0 mg/mL (1.0 mg per 100 µL / 0.1 mL). • 2.0 mL Diluent Volume: Reconstituting a 10 mg vial with 2.0 mL of bacteriostatic water yields a stock concentration of 5.0 mg/mL (0.5 mg per 100 µL / 0.1 mL). • 3.0 mL Diluent Volume: Reconstituting a 10 mg vial with 3.0 mL of bacteriostatic water yields a stock concentration of approximately 3.33 mg/mL (0.33 mg per 100 µL / 0.1 mL). • 5.0 mL Diluent Volume: Reconstituting a 10 mg vial with 5.0 mL of bacteriostatic water yields a stock concentration of 2.0 mg/mL (0.2 mg per 100 µL / 0.1 mL).

For custom vial masses or non-standard diluent additions, researchers can verify concentration values dynamically using our interactive reconstitution calculator.

The Arithmetic Behind Peptide Concentration Calculations

Calculating peptide concentration requires applying basic volumetric mass equations. The foundational equation governing concentration ($C$) is expressed as the total mass of the active lyophilized solute ($m$) divided by the total liquid volume of diluent added ($V$): $C = m / V$.

When calculating the resulting concentration for a 10 mg vial of PT-141 reconstituted with 2.0 mL of bacteriostatic water, the arithmetic proceeds as follows: $C = 10\text{ mg} / 2.0\text{ mL} = 5.0\text{ mg/mL}$. To determine the mass delivered in a specific pipette sample volume (e.g., 50 µL or 0.05 mL), multiply the sample volume by the stock concentration: $0.05\text{ mL} \times 5.0\text{ mg/mL} = 0.25\text{ mg}$ (250 µg).

Understanding this simple relationship prevents errors during serial dilutions or cell-culture media preparations. Standardizing concentration calculations across experimental runs ensures reproducible data across preclinical binding studies and enzymatic assays. For additional methodology details on laboratory calculations, visit the PX1 Research library.

Step-by-Step Laboratory Reconstitution Protocol

Reconstitution should be conducted within a certified laminar flow hood or clean bench utilizing aseptic technique to preserve peptide integrity and prevent contamination. Equilibrate the lyophilized PT-141 vial and bacteriostatic water to room temperature (20°C to 25°C) prior to fluid addition to minimize thermal shock to the peptide matrix.

Sanitize the rubber septum of the peptide vial using a 70% isopropyl alcohol swab and allow it to air-dry completely. Using a sterile lab syringe, draw the predetermined volume of bacteriostatic water (e.g., 2.0 mL). Insert the needle through the center of the rubber stopper at a slight angle and direct the stream of water down the glass wall of the vial rather than shooting it directly onto the lyophilized cake.

Allow the liquid to gradually saturate the powder. Gently swirl the vial in a smooth circular motion until the cake is completely dissolved. Never shake, vortex aggressively, or subject the solution to high mechanical shear stress, as rapid agitation can cause peptide aggregation or denaturation of the tertiary structure.

Aliquoting, Storage, and Stability Guidelines

Once fully reconstituted into solution, PT-141 exhibits reduced thermodynamic stability relative to its dry lyophilized state. To avoid repeated freeze-thaw cycles—which degrade peptide backbones through ice crystal formation and physical stress—reconstituted solutions should be sub-aliquoted into micro-centrifuge tubes using low-binding polypropylene plasticware.

Reconstituted PT-141 dissolved in bacteriostatic water (containing 0.9% benzyl alcohol) can be stored under refrigeration at 2°C to 8°C for short-term active experimental workflows. For extended storage requirements exceeding 28 days, reconstituted aliquots should be rapidly frozen at -20°C or -80°C.

Lyophilized vials, prior to reconstitution, maintain high stability when stored at -20°C protected from ambient light and moisture ingress. Laboratory investigators requiring bulk quantities for long-term experimental programs can access scaled supply arrangements through our wholesale account portal.

Melanocortin Receptor Signaling Mechanisms

PT-141, chemically designated as Bremelanotide, is a synthetic cyclic heptapeptide analog derived structurally from Alpha-Melanocyte-Stimulating Hormone (α-MSH). Unlike non-selective melanocortin peptides, PT-141 operates primarily as a high-affinity agonist at central melanocortin receptors, displaying prominent activity at the MC3R and MC4R subtypes within the central nervous system.

Preclinical studies suggest that activation of central MC4R pathways modulates central neurochemical signaling pathways involved in sexual-health research and behavioral response cascades. In animal models, central melanocortin agonist administration triggers downstream neuronal firing across hypothalamic nuclei without directly activating vascular adrenergic systems.

In vitro binding assays demonstrate that PT-141 binds to human recombinant MC4R with nanomolar affinity ($K_i$), making it a valuable tool compound for evaluating central receptor crosstalk, energy homeostasis, and neuroendocrine signaling networks. For further scientific background on central receptor ligands, review our research articles.

Comparative Analysis: PT-141 vs. Melanotan II and Related Peptides

PT-141 is structurally related to other synthetic melanocortin receptor ligands but exhibits distinct receptor selectivity profiles and functional biological activities. Comparing these structural analogs aids researchers in selecting the appropriate molecule for specific signaling or receptor binding assays.

• Melanotan II: MT-2 is a cyclic heptapeptide precursor from which PT-141 was developed. MT-2 acts as a potent non-selective agonist across MC1R, MC3R, MC4R, and MC5R. Consequently, MT-2 exhibits strong peripheral melanogenesis activity via MC1R alongside central nervous system effects. • PT-141 (Bremelanotide): PT-141 lacks the C-terminal amide structure of MT-2, shifting its primary affinity away from peripheral MC1R melanocyte activation toward central MC3R and MC4R signaling pathways. This distinction makes PT-141 the preferred candidate for neurobehavioral research. • Setmelanotide: Setmelanotide is an oligopeptide melanocortin agonist engineered specifically for high selectivity at MC4R, widely investigated in preclinical models of metabolic signaling and hyperphagia.

Selecting among these compounds depends on whether an assay targets peripheral melanogenesis (MC1R) or central hypothalamic receptor signaling (MC3R/MC4R).

Quality Verification: Purity, COA, and Endotoxin Control

Experimental integrity in cell-culture and receptor-binding research depends on reagent purity and batch consistency. Low-purity peptide preparations can introduce chemical artifacts, non-specific binding, or cellular toxicity that compromises analytical results.

Every lot of PT-141 produced for PX1 Research undergoes stringent third-party quality testing in ISO 17025 accredited analytical laboratories within the United States. Purity is validated via High-Performance Liquid Chromatography (HPLC), guaranteeing a minimum sequence purity of 99%. Molecular weight and peptide sequence identity are confirmed using Mass Spectrometry (MS).

Additionally, because bacterial endotoxins (lipopolysaccharides) can contaminate recombinant or synthetic preparations and induce non-specific inflammatory responses in vitro, PX1 Research subjects every batch to Chromogenic LAL endotoxin testing. Researchers can review lot-specific analytical reports directly through our published certificate of analysis directory.

Troubleshooting Reconstitution and Solubility Issues

Although lyophilized PT-141 possesses excellent solubility in aqueous buffers, environmental factors or physical handling errors can occasionally cause incomplete dissolution or visible particulate formation.

If persistent micro-particulates remain after adding bacteriostatic water, verify that the solution pH is near physiological neutral (pH 6.5–7.4). PT-141 exhibits optimal aqueous solubility in standard neutral or slightly acidic diluents. Avoid using highly basic diluents, which can cause target peptide precipitation or accelerated alkaline hydrolysis.

In cases where dissolution is slow, allow the vial to stand quiescently at room temperature for 10–15 minutes to permit full hydration of the peptide cake. Gentle inversion may be applied; however, ultrasonic bath sonication should be avoided as localized cavitation energy can degrade delicate peptide backbones.